Efficacy and Safety of Datopotamab Deruxtecan in Patients with Pretreated Advanced/Metastatic NSCLC with Actionable Genomic Alterations By Ogkologos - January 27, 2025 420 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPION-Lung05 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Study Identifies Potential Drug Target to Prevent Some Liver Cancers February 4, 2022 Mom Finding Out Baby’s Gender Uncovers Rare Condition When Doctors See... November 7, 2019 FDA Grants Accelerated Approval to Amivantamab-vmjw for Metastatic NSCLC with EGFR... May 28, 2021 Living With Metastatic Breast Cancer: How I Reinvented Myself October 30, 2020 Load more HOT NEWS Finding Hope in the New Year During COVID-19 and Cancer Doctors Say Girl Has ‘Vanishing Bones’ That Are Slowly Disappearing From... Trial Suggests Expanded Role for Blinatumomab in Treating ALL FDA Approves Ivosidenib in Combination with Azacitidine for Newly Diagnosed AML
